These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19823041)

  • 1. Antiandrogens in the 21st century.
    Pisle ST; Figg WD
    Cancer Biol Ther; 2009 Sep; 8(17):1611. PubMed ID: 19823041
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiandrogens: medical treatment of prostate cancer].
    Gerson C
    Soins; 1995; (598):69-70. PubMed ID: 8701346
    [No Abstract]   [Full Text] [Related]  

  • 3. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 5. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
    Sogani PC; Whitmore WF
    Cancer Treat Res; 1988; 39():131-45. PubMed ID: 2908604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogens in prostate cancer.
    Reid P; Kantoff P; Oh W
    Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogenic substances in the management of prostatic cancer.
    Schröder FH
    Recent Results Cancer Res; 1990; 118():163-73. PubMed ID: 2146723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and clinical use of antiandrogens: a short review.
    Neumann F
    Ir J Med Sci; 1982 Mar; 151(3):61-70. PubMed ID: 7042638
    [No Abstract]   [Full Text] [Related]  

  • 13. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
    Ellwood-Yen K; Wongvipat J; Sawyers C
    Cancer Res; 2006 Nov; 66(21):10513-6. PubMed ID: 17079473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fundamental and clinical study on antiandrogens--androgen-dependency of prostatic tumors and clinical application of antiandrogens (author's transl)].
    Shida K
    Horumon To Rinsho; 1980 Aug; 28(8):899-928. PubMed ID: 6161722
    [No Abstract]   [Full Text] [Related]  

  • 16. Design of antiandrogens and their mechanisms of action: a case study (anandron).
    Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
    Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
    Fujii S; Kagechika H
    Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells.
    Miyamoto H; Chang C
    Int J Urol; 2000 Jan; 7(1):32-4. PubMed ID: 10701889
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.